Bullish & Foolish
Full BCAB fundamentals All 466 on the Survival Watch

BCABBIOATLA, INC.

Is Bioatla struggling financially?

Yes, by its own account. Bioatla told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$5.3M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$1.5M

÷

Cash burned over the last 12 months

$59.2M

What Bioatla told the SEC

…of at least twelve months from the date the condensed consolidated financial statements included in this report are issued, and these circumstances raise substantial doubt about our ability to continue as a going concern. Financial Operations Overview Revenue To date, we have not generated any revenue from the sale of products and do not expect to generate meaningful revenue in the near future. We have…

BIOATLA, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 50% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt